Grant: Discovery Grants Program - Individual
University of Waterloo
$20,000.00
Recombinant protein bioprocess optimization using emerging expression platforms
EF 2010-11
Résumé
Since the first recombinant product in 1982, the biopharma industry has experienced an unprecedented growth in Canada with sales approaching $10billion annually. The conventional platforms expressing many biopharmaceuticals (animal cell lines and Escherichia coli) have some drawbacks. To alleviate these, the engineering assessment and optimization of fed-batch cultures of two alternate, emerging recombinant hosts, namely Pichia pastoris (a eukaryote) and Streptomyces lividans (a prokaryote) expressing human interleukin-3 (huIl-3) are proposed as model systems for study. The proposed research is built upon the applicant's experience with recombinant protein bioprocesses. The objective is to develop a model-based optimization strategy for manipulating the nutrient feed and operating conditions in order to maximize the recombinant protein productivity and the concentration. A structured experimental approach and data analysis will be required to fully optimize the process. As a first step a stoichiometry-based metabolic flux model will be constructed to detail catabolic pathways, biosynthesis, and gene regulation. The full flux model will be simplified and fine-tuned by statistical methods. Potential bottlenecks affecting optimum expression will be identified. The metabolic flux model will be applied, in turn, to establish a balanced medium to reduce metabolic stress that may lead to product degradation.. Control routines will be developed and optimized so as to produce robust process trajectories in batch and fed-batch culture. An important aspect of the experimental work is to identify probable mass transfer limitations in high density culture and apply corrective measures if necessary. The resulting data will then be used as the basis for optimization of the bioprocesses using both in situ and ex-situ instrumentation.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
4695-2008
Name nom
Scharer, Jeno
Department département
Chemical Engineering
Organization id
33
Institution établissement
University of Waterloo
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2010
Competition year année de concours
2008
Award amount
20000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
4
Committee name en
Chem. & Metallurgical Eng.
Committee name fr
Génies chimique et métal.
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
1802
Research subject group en
Chemical engineering
Research subject group fr
Génie chimique
Research subject en
Biochemical engineering
Research subject fr
Génie biochimique
Partie
3
Nb partie
3
Application title
Recombinant protein bioprocess optimization using emerging expression platforms
Keyword
NSERC
Application summary
Since the first recombinant product in 1982, the biopharma industry has experienced an unprecedented growth in Canada with sales approaching $10billion annually. The conventional platforms expressing many biopharmaceuticals (animal cell lines and Escherichia coli) have some drawbacks. To alleviate these, the engineering assessment and optimization of fed-batch cultures of two alternate, emerging recombinant hosts, namely Pichia pastoris (a eukaryote) and Streptomyces lividans (a prokaryote) expressing human interleukin-3 (huIl-3) are proposed as model systems for study. The proposed research is built upon the applicant's experience with recombinant protein bioprocesses. The objective is to develop a model-based optimization strategy for manipulating the nutrient feed and operating conditions in order to maximize the recombinant protein productivity and the concentration. A structured experimental approach and data analysis will be required to fully optimize the process. As a first step a stoichiometry-based metabolic flux model will be constructed to detail catabolic pathways, biosynthesis, and gene regulation. The full flux model will be simplified and fine-tuned by statistical methods. Potential bottlenecks affecting optimum expression will be identified. The metabolic flux model will be applied, in turn, to establish a balanced medium to reduce metabolic stress that may lead to product degradation.. Control routines will be developed and optimized so as to produce robust process trajectories in batch and fed-batch culture. An important aspect of the experimental work is to identify probable mass transfer limitations in high density culture and apply corrective measures if necessary. The resulting data will then be used as the basis for optimization of the bioprocesses using both in situ and ex-situ instrumentation.